Sensorion

140 articles about Sensorion

• Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss

  11/7/2022

  Sensorion announces that the US Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

• Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

  10/24/2022

  Sensorion announces that the initiation of a Proof of Concept clinical trial of SENS-401 in patients with Cisplatin-Induced Ototoxicity has been approved by regulatory authorities in France.

• Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022

  10/6/2022

  Sensorion is pleased to announce Sensorion's participation in two scientific conferences in October 2022.

• Sensorion to Participate in Various Upcoming September 2022 Investor Conferences

  9/26/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of Sensorion’s management in various upcoming investor conferences.

• Sensorion Reports 2022 First Half Results

  9/22/2022

  Sensorion announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.

• Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

  9/14/2022

  Sensorion announces that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 in patients scheduled for cochlear implantation.

• Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency

  9/12/2022

  Sensorion announces that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion on Sensorion’s application for Orphan Drug Designation for its lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

• Sensorion to participate in the Inner Ear Biology Workshop in September 2022

  9/8/2022

  Sensorion is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, Italy.

• Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022

  7/7/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion’s management in three scientific conferences in July 2022.

• Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

  7/1/2022

  Sensorion announces that the initiation of a Proof of Concept clinical trial of SENS-401 in patients scheduled for cochlear implantation has been approved by regulatory authorities in Australia.

• Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022

  6/24/2022

  Sensorion is pleased to announce the participation of CEO Nawal Ouzren in the LifeSci Partners 2nd Annual Genetic Medicines Symposium being held virtually on June 28-29, 2022.

• Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022

  6/15/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in-person of members of Sensorion’s senior management in the Inner Ear Disorder Therapeutics Summit, a scientific conference being held in Boston, USA, in June 2022.

• Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022

  6/9/2022

  Sensorion is pleased to announce the participation in-person of a member of Sensorion’s senior management in the Gene Therapy Development and Manufacturing conference being held in London, UK, in June 2022.

• Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

  6/7/2022

  Sensorion announces, that the initiation of a Proof of Concept clinical trial of SENS-401 in patients scheduled for cochlear implantation has been approved by regulatory authorities in France.

• Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022

  5/12/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of Sensorion’s management in two scientific conferences being held in May 2022.

• Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022

  5/10/2022

  Sensorion announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Tuesday, May 31, 2022, at 2 pm CET in the premises of the hotel L’Arcade, located at 9 rue de l’Arcade, 75008, Paris.

• Sensorion Full-Year 2021 Financial Results and Business Highlights

  4/28/2022

  Sensorion announces its full-year 2021 financial results and provides an update on its business activities and outlook for 2022.

• Sensorion Announces the Publication of Its 2021 Annual Financial Report

  4/28/2022

  Sensorion announces that its annual financial report for the year ending December 31, 2021, is available to the public and filed with the French financial market authority.

• Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022

  4/21/2022

  Sensorion is pleased to announce the participation of CEO Nawal Ouzren in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, being held virtually on April 25-26, 2022.

• Sensorion to Attend the Kempen Life Sciences, Cell & Gene Meeting on the Mediterranean Conferences in April 2022

  4/12/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that CEO Nawal Ouzren will attend in person two investor meetings in April 2022.